Delving into the Latest Updates on Antengene (Hangzhou) Biologics Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Digestive System Disorders

Hemic and Lymphatic Diseases

Antibody drug conjugate (ADC)

Antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Hemic and Lymphatic Diseases	1
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Antibody	1
Antibody drug conjugate (ADC)	1

Top 5 Target	Count

CLDN18.2(Claudin 18.2)	1
CLDN18.2 x Tubulin	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 01 Feb 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Phase 2

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

ATG-022 ( CLDN18.2 x Tubulin )	Advanced Malignant Solid Neoplasm More	Phase 1
WO2024250437 ( CLDN18.2 )Patent Mining	Hematologic Diseases More	Discovery
Xirestomig ( 4-1BB x PDL1 )	Solid tumor More	Discontinued